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Use of Cilostazol for Secondary Stroke Prevention: An Old Dog with New Tricks?
Alexander J Ansara, Dane L Shiltz, Jennifer B Slavens

Abstract
OBJECTIVE: To evaluate the safety and efficacy of cilostazol for secondary prevention of noncardioembolic ischemic stroke.
DATA SOURCES: PubMed and MEDLINE searches were performed (January 1970-September 2011)
using the key words cilostazol, antiplatelet, aspirin, acetylsalicylic acid, secondary stroke prevention,
ischemic stroke, intracerebral hemorrhage, intracranial, cerebrovascular accident, and transient ischemic
attack. Additionally, reference citations from publications identified were reviewed.
STUDY SELECTION AND DATA EXTRACTION: Articles published in English and relevant
primary literature evaluating the efficacy and safety of cilostazol in the secondary prevention of
atherosclerotic ischemic stroke were included.
DATA SYNTHESIS: Antiplatelet therapy plays a vital role in the multifaceted approach to secondary
stroke prevention. Current American Heart Association/American Stroke Association clinical guidelines
for secondary stroke prevention support the use of aspirin, clopidogrel, and combination aspirin/extendedrelease dipyridamole. The antiplatelet, antithrombotic, and vasodilatory effects of cilostazol make it a
potential alternative agent for atherosclerotic stroke prevention. Recent literature has demonstrated
superior efficacy of cilostazol 100 mg twice daily for secondary stroke prevention compared to placebo
and aspirin. Three clinical trials were reviewed (1 placebo-controlled, 2 aspirin-controlled), all of which
were conducted in Japan or China. Cilostazol reduced the primary outcome of recurrence of stroke, with
significantly fewer major bleeding events when compared to aspirin.
CONCLUSIONS: Available literature suggests that cilostazol may be safer and more effective than
aspirin in the secondary prevention of stroke in Asian patients. Further large-scale studies in more
heterogeneous study populations are warranted to determine whether cilostazol is a viable therapeutic
option for patients with a history of non-cardioembolic ischemic stroke.

Stroke is the third leading cause of death in the US, accounting for 1 of every 18 deaths in 2007.1
While stroke death rates have fallen from 33.5% in 1996 to 16.7% in 2007, stroke remains a
leading cause of disability, impaired functionality, and reduced quality of life.1
Atherosclerotic disease accounts for roughly 85% of the nearly 800,000 strokes that occur
annually in the US.1 Optimization of secondary stroke prevention requires a multifaceted
approach that includes blood pressure control, cholesterol-lowering medications, smoking
cessation, diet, and exercise, among others. Another mainstay of stroke prevention is antiplatelet
therapy. Several antiplatelet agents, including aspirin, clopidogrel, ticlopidine, and
aspirin/extended-release dipyridamole, are currently recommended by the American Heart
Association (AHA) and American Stroke Association as suitable options for secondary stroke
prevention.2
Aspirin is often prescribed as a first-line agent for secondary stroke prevention due to its lack of
therapeutic monitoring, established efficacy in the treatment of acute ischemic stroke, and

significantly lower cost compared to all other antiplatelet agents. While the cost of aspirin is
significantly the lowest among these antiplatelet agents, its use is associated with dosage-related
gastrointestinal (GI) and intracranial hemorrhages (ICH).3 Ticlopidine and clopidogrel use is
associated with neutropenia, diarrhea, and skin rash, while up to 40% of patients taking
aspirin/extended-release dipyridamole experience severe headaches.4⇓–6
Recent clinical trial evidence suggests that cilostazol, a platelet inhibitor indicated for
intermittent claudication, may be a safer and more effective alternative than aspirin for secondary
stroke prevention in Asian patients. AHA guidelines do not yet provide recommendations on the
role of cilostazol for secondary stroke prevention. This article details cilostazol's mechanism of
action as an antiplatelet agent, provides a critique of secondary ischemic stroke prevention trials
(all conducted in either Japan or China), and compares bleeding rates with cilostazol to those of
other secondary stroke prevention treatment options.
Data Sources
A literature search was performed (January 1970-September 2011) using PubMed and
MEDLINE to identify relevant English-language review articles and clinical trials using the key
words cilostazol, antiplatelet, aspirin, acetylsalicylic acid, secondary stroke prevention, ischemic
stroke, intracerebral hemorrhage, intracranial, cerebrovascular accident, and transient ischemic
attack. Reference citations of identified articles were used to identify additional literature for
reference. Data from package inserts and unpublished clinical trials in progress (from
www.clinicaltrials.gov) were also reviewed. Article selection was focused on the pharmacology
of antiplatelet agents, the pathophysiology of atherosclerotic stroke, clinical trials, and safety
analyses.
Mechanism of Action
Atherosclerotic vascular plaques contain smooth muscle cells, macrophages, and collagen within
a lipid core. Plaque erosion, fissure, and/or rupture due to shear stress expose the subendothelial
matrix, collagen, and tissue factor found within the lipid core. Each of these serves as potent
substrates for platelet-rich thrombus formation.7
Following rupture of unstable plaques, tissue factor and collagen-bound von Willebrand factor
promote platelet adhesion and activation on the exposed subendothelial matrix surface. Activated
platelets release adenosine diphosphate (ADP) and cyclooxygenase (COX)-produced
thromboxane A2, mediators that promote vasoconstriction and additional platelet activation.
Through the P2Y12 receptor, ADP stimulates platelets to express glycoprotein IIb/IIIa receptors.
Glycoprotein IIb/IIIa receptors cross-link platelets via fibrinogen that is further cleaved into
fibrin by activated thrombin (factor IIa) to form a stable thrombus. This thrombus occludes blood
flow through vessels, depriving tissues of necessary oxygen, and potentially contributing to cell
and tissue death.7
Cilostazol's utility as a medication for ischemic stroke prevention extends from its Food and
Drug Administration (FDA)–approved indication for the treatment of intermittent claudication in
peripheral arterial disease because it exerts antiplatelet, antithrombotic, and vasodilatory effects.5

As a dose-dependent antiplatelet agent with a 3- to 6-hour onset, cilostazol blocks platelet
adenosine uptake and adenosine-induced platelet activation to prevent platelet aggregation.
Additional antiplatelet and antithrombotic actions involve platelet- and endothelial-derived
phosphodiesterase type 3 (PDE-3) enzyme inhibition.8,9 Intraplatelet cyclic adenosine
monophosphate (cAMP) elevations due to PDE-3 inhibition prevent platelet aggregation and
thrombus formation stimulated by thrombin, arachidonic acid, ADP, epinephrine, collagen, and
sheer physical stress (Figure 1).7,9–11 In vitro and in vivo data further demonstrate that cilostazol
induces the expression of the endothelium-derived antiplatelet compound prostacyclin, while the
COX inhibitor aspirin prevents prostacyclin formation, allowing for platelet aggregation.7,9

Figure 1 Cilostazol mechanisms of action. Atherosclerotic plaque rupture permits binding of TF and vWF to exposed collagen
and subendothelial matrix to initiate the platelet activation process. Following platelet activation, platelet adenosine
concentrations increase through reuptake while cAMP concentrations decrease through the PDE-3 enzyme metabolism. In
combination with thrombin, epinephrine, ADP and other mediators, these actions serve to promote platelet aggregation and
thrombus formation.7 Cilostazol inhibits PDE-3 to maintain cAMP levels while preventing platelet adenosine uptake. These
principal actions prevent platelet aggregation, augment production of the antiplatelet prostacyclin, decrease response to platelet
stimuli such as thrombin, epinephrine, and ADP, and also vasodilate major blood vessels that perfuse organs including the brain,
heart, and extremities.9⇓–11 ADP = adenosine diphosphate; cAMP = cyclic adenosine monophosphate; PDE-3 =
phosphodiesterase type 3; PGI2 = prostacyclin; TF = tissue factor; vWF = von Willebrand factor.

Compared to cilostazol, aspirin/extended-release dipyridamole also prevents platelet adenosine
uptake, but also inhibits cyclic guanosine monophosphate to prevent platelet activation. The
aspirin component inhibits the COX enzyme to prevent thromboxane A2 production, platelet
aggregation, and vasoconstriction.6 Clopidogrel is another FDA-approved antiplatelet agent used
for secondary stroke prevention. Clopidogrel is activated via the CYP2C19 enzyme to selectively
and irreversibly inhibit the binding of ADP to its platelet P2Y12 receptor and the subsequent

ADP-mediated activation of the glycoprotein IIb/IIIa complex, thereby inhibiting platelet
aggregation.5
Cilostazol reduces vascular tone, promoting more vasodilation in vertebral and femoral arteries
than renal arteries.10 Cilostazol also increases human carotid, cerebral, coronary, and dermal
blood flow.9,10 Additional effects on vasculature include inhibition of human smooth muscle
proliferation due to growth factors including insulin, insulin-like growth factor, serum growth
factor, and platelet-derived growth factor. Emerging evidence suggests that, by inhibiting the
PDE-3 enzyme found within human smooth muscle cells, cilostazol inhibits smooth muscle cell
proliferation and thus may prevent and possibly even reverse intracranial atherosclerotic lesions,
improving cerebral blood flow.12,13 Additionally, cilostazol increases vascular endothelial growth
factor, which serves to repair damaged vascular epithelium.9,10 These combined antiplatelet,
antithrombotic, and vascular properties all favorably contribute to cilostazol's utility for stroke
prevention.
Clinical Trials
Three clinical trials encompass the body of evidence supporting the use of cilostazol as an
alternative agent for secondary stroke prevention in Asian patients. These clinical trials include
the placebo-controlled CSPS (Cilostazol Stroke Prevention Study) and 2 aspirin-controlled trials:
the CASISP (Cilostazol as an Alternative to Aspirin After Ischaemic Stroke) trial and the CSPS2 (Cilostazol for Prevention of Secondary Stroke) trial. Comparisons and findings of these trials
are summarized in Table 1.11,14,15
The impetus for conducting these trials was a relative lack of representation of Asian patients in
stroke prevention studies, as most large-scale trials had been conducted in North American and
Western European countries. Compared to other ethnic categories, the prevalence of 2 or more
risk factors (diabetes, smoking, high blood pressure or cholesterol, obesity, physical inactivity)
for stroke is lowest among Asian Americans (25.9%)16; therefore, the age-adjusted prevalence of
stroke among Asian Americans 18 years of age and over remains relatively low, at 1.3%.17
However, the age-adjusted incidence of ICH for individuals 55 years and older in the Chinese
population is higher than that seen in individuals in Western populations.18,19 While the primary
goal of antiplatelet therapy is to prevent ischemic events, minimizing the risk of ICH remains an
essential focus of stroke prevention therapy.

Table 1. Secondary Stroke Prevention Trials Utilizing Cilostazol
Study
Patient
Patient Characteristics
Treatmen
s
t Arms
(N)
CSPS
(2000)14

1052

65% male; median age 65 y;
65% MCA stroke; 75%
small infarction (≤1.5 cm);
61% HTN; 51% <60 days
since CVA

Cilostazol
100 mg
bid vs
placebo

Treat
ment
Durat
ion
1.7
Years

Primary
Endpoint

Results

p Value

Cerebral
infarction

Event rate
0.015 (95% CI
per year:
9.2% to 62.5%)
cilostazol
3.37% vs
placebo
5.78% (RRR
= 41.7%)
CASISP
719
69% male; median age 60 y;
Cilostazol 1 year Any stroke:
Composite
0.62 (95% CI 0.3 to
(2008)15
82% modified Rankin scale
100 mg
Ischemic
endpoint:
1.26)
score ≤2; 79% HTN; 62% on bid
stroke,
cilostazol
aspirin at baseline; 18%
vs aspirin
cerebral
3.62% vs
daily history of DM
100 mg
hemorrhage,
aspirin
subarachnoid 6.41% (540hemorrhage
day
estimated
recurrence
rates)
CSPS-2
2672
72% male; mean age 63 y;
Cilostazol 2.4
Any stroke:
Composite
Composite
(2010)11
92% Rankin scale score ≤ 2;
100 mg
years
cerebral
endpoint:
endpoint:
82% <2 months post-stroke;
bid
infarction,
cilostazol
p = 0.0357
73% HTN; 42%
vs aspirin
cerebral
2.76%/y
(95% CI 0.564 to
hyperlipidemia; 58% on
81 mg
hemorrhage,
vs aspirin
0.981) Ischemic
aspirin at baseline; 25% on
daily
subarachnoid 3.71%/y
stroke: p = 0.419
cilostazol at baseline
hemorrhage
Ischemic
(95% CI 0.65 to
stroke:
1.2)
cilostazol
2.43%/y vs
aspirin
2.75%/y
CASISP = Cilostazol as an Alternative to Aspirin After Ischaemic Stroke; CSPS = Cliostazol Stroke Prevention Study; CSPS-2 =
Cilostazol for Prevention of Secondary Stroke; CVA = cerebrovascular accident; DM = diabetes mellitus; HTN = hypertension; MCA =
middle cerebral artery; RRR = relative risk reduction.

CILOSTAZOL STROKE PREVENTION STUDY
The CSPS was an intention-to-treat study conducted in Japan at 183 clinical institutions from
April 1992 to March 1996. Patients (N = 1052; 65% male) less than 80 years old with a prior
cerebral infarction were randomized in a double-blinded manner to receive cilostazol 100 mg
orally twice daily (n = 526) or placebo (n = 526) starting 1-6 months after infarction.14 Patients
with ICH, cardiogenic emboli, hemostatic disorders, need for non-study antiplatelet agents,
severe cerebral deficit, dementia, or a wide variety of cardiac valve or chamber-associated
complications were excluded, as were any pregnant or nursing women. The primary endpoint
was the recurrence of cerebral infarction. Secondary endpoints included all-cause mortality, ICH,
transient ischemic attack (TIA), and multiple composite endpoints including the composite of
cerebral infarction, ICH, or TIA. Safety and adverse effects were also assessed on 4 occasions,
including 2 interim analyses that also included assessments of efficacy.
Mean time from the primary cerebrovascular accident until treatment initiation was 83 days in
both treatment arms and mean duration of follow-up was 1.7 years. While the 83-day mean time
to treatment initiation with cilostazol appears inappropriate for a secondary stroke prevention
study, many patients were already receiving secondary stroke prevention with various other

anticoagulant and antiplatelet agents. However, the authors do not identify the medications,
doses, or percentages of patients utilizing these medications prior to study initiation. Baseline
characteristics of age (65 years), blood pressure, infarction size, and past medical histories were
comparable in both groups. Additionally, the involved arteries of the primary cerebrovascular
infarction were comparable in both groups: middle cerebral arteries (64.7% and 66.3%) and
vertebrobasilar arteries (19.5% and 21.3%) accounted for the majority of the infarctions in the
cilostazol and placebo groups, respectively. It is noteworthy that approximately 75% of all
primary cerebral infarctions were lacunar infarcts,14 a form of small artery occlusive stroke
associated with the lowest rates of early recurrence and best rates of survival and motor deficit
improvements among the various types of strokes.20
Treatment with cilostazol was associated with reductions in the recurrence of cerebral infarction,
as 30 and 57 strokes occurred in the cilostazol and placebo groups, respectively (event rates
3.37%/year vs 5.78%/year; p = 0.015).14 This correlated to a relative risk reduction (RRR) of
41.7% and a number needed to treat (NNT) of 42 patients. The greatest risk reduction (43.4%
with cilostazol vs placebo; p = 0.0373) occurred in patients with initial lacunar infarcts, a finding
that suggests that cilostazol may have a specific effect against small-vessel cerebrovascular
disease.21 Treatment with cilostazol was also associated with favorable effects on the composite
endpoint of cerebral infarction, ICH, or TIA (event rates 4.17%/year vs 7.06%/year; RRR 40.9%;
p = 0.009) as well as rates of all-cause mortality during the trial period (RRR 43.8%; p =
0.042).14
ICH developed in 4 patients receiving cilostazol and 7 patients receiving placebo. While no
ischemic or hemorrhagic strokes were fatal in the cilostazol group, there were 3 ischemic and 1
hemorrhagic fatal strokes among the 534 patients in the placebo group. Patients receiving
cilostazol reported significantly higher rates of mild headaches (12.8% vs 3.2%), palpitations
(5.3% vs 0.4%), and elevated heart rates (19.0% vs 7.9%), most of which were often self-limited.
A higher percentage of patients in the cilostazol group experienced reductions in serum
triglycerides (6.6% cilostazol vs 2.9% placebo; p = 0.0097) and elevations in high-density
lipoprotein levels (14.3% cilostazol vs 5.2% placebo; p = 0.00), although specific data on the use
of lipid-lowering agents in study participants were not provided. The investigators also did not
define, nor quantify, what entailed a reduction in triglyceride levels or an increase in highdensity lipoprotein levels.14 The reductions in stroke associated with cilostazol are more likely
attributed to the antiplatelet and vasodilatory effects that result from cAMP-phosphodiesterase
inhibition and not the antilipidemic effects observed in this trial.22,23 These vasodilatory effects
also explain the significantly higher rates of headaches reported in subjects receiving cilostazol.14
The ethicality of this placebo-controlled stroke trial can be questioned given that the
AHA/American Stroke Association secondary stroke guidelines suggest antiplatelet drugs with a
level I class A evidence recommendation in this study population.2 The findings demonstrate that
cilostazol reduces the recurrence of cerebrovascular infarctions compared to placebo.14 The
beneficial effects of cilostazol were apparent early, continued throughout the study, and were
comparable in men and women, without increased rates of cerebral hemorrhage. Based on the
CSPS data, the pilot CASISP study and larger CSPS-2 study were designed to assess the efficacy
and safety of cilostazol as a direct comparator to aspirin in the setting of secondary stroke
prevention.

CILOSTAZOL AS AN ALTERNATIVE TO ASPIRIN AFTER ISCHEMIC STROKE
Following the published results of the CSPS, data were still lacking on cilostazol versus an active
comparator. In 2008, Huang and colleagues published CASISP, an intent-to-treat trial designed
to assess the safety and efficacy of cilostazol versus aspirin for secondary stroke prevention.15
CASISP was a randomized, double-blind, multicenter, pilot trial that enrolled 719 Chinese
patients (69% male) who had experienced an image-diagnosed ischemic stroke. Patients were
randomized to receive cilostazol 100 mg orally twice daily (n = 360) or aspirin 100 mg orally
once daily (n = 359) starting 1-6 months after infarction. Patients were followed for 12-18
months and evaluated on the primary outcome of recurrence of stroke as defined by any of the
following: ischemic stroke, cerebral hemorrhage, or subarachnoid hemorrhage. Patients with a
history of subarachnoid hemorrhage, ICH, cardioembolic cerebral infarct, contraindication to
antiplatelet therapy, use of antiplatelet therapy other than cilostazol during the study period,
severe disability, uncontrolled severe comorbidities, or modified Rankin scale score of 4 or
greater were not eligible for inclusion in this study. A score of 4 or greater on the modified
Rankin scale (which assigns a number between 0 and 6 to assess a patient's level of
independence after stroke) represents moderate-to-severe disability, including patients unable to
walk without assistance or bedridden patients requiring constant nursing care. A score of 6 is
assigned for death.24,25 Specific uncontrolled severe comorbidities and disabilities qualifying
patients for exclusion were not stated.15 Patients with hypertension and dyslipidemia at baseline
were given antihypertensives and/or statins. No statement of specific agents utilized, number of
patients affected in each treatment group, or criteria to define hypertension or dyslipidemia were
disclosed.
Baseline characteristics were similar between the 2 groups. Systolic blood pressure was
significantly higher in the aspirin group at baseline (p = 0.03). These patients were treated with
antihypertensives, with resolution of hypertension after 1 month of therapy. No statements of the
medications utilized, number of patients treated for hypertension, or goal blood pressure were
made. Sixty-two percent of the patients in both groups were taking aspirin prior to enrollment.
One percent or less of the patients in each group was on cilostazol prior to enrollment. A
majority (82%) of the patients in both groups had a modified Rankin scale score of 2 or less.15
The primary endpoint was reached by 12 patients (3.33%) in the cilostazol group and 20 patients
(5.57%) in the aspirin group, resulting in an RRR of 38.1% (95% CI 0.3 to 1.26%; p = 0.18).
Ischemic strokes occurred in 26 patients: 11 with cilostazol (3.1%) and 15 with aspirin (4.2%),
but this finding also did not reach statistical significance. As a component of the primary
endpoint, hemorrhagic strokes accounted for 8% of the cilostazol-related strokes (1/12) and 25%
of the aspirin-related strokes (RR 7.14; p = 0.038). New microbleeds and asymptomatic
hematomas were reported less commonly in the cilostazol group than in the aspirin group;
however, no statement of significance was disclosed. Other adverse effects reported more
frequently in the cilostazol group were headache, dizziness, palpitations, and tachycardia.
Extracranial bleeding was reported more frequently in the aspirin group (4% cilostazol vs 9%
aspirin). Fecal occult bleeding, hematuria, GI bleeding, and rhinorrhagia were common types of
extracranial bleeding.15

Results of this study support a trend toward improved efficacy of cilostazol over aspirin and
improved safety, shown by the statistically significant reduction in bleeding events in the
cilostazol group.15 The finding that hemorrhagic stroke occurred less frequently with cilostazol is
salient considering the higher incidence of cerebral hemorrhage in patients of Asian ethnicity
relative to other ethnic groups.26,27 Nevertheless, based on the hypothesis-generating results of
the CASISP trial, further analysis in a large Phase 3 trial was warranted to evaluate the trend
toward improved efficacy of cilostazol over aspirin for secondary stroke prevention.
CILOSTAZOL STROKE PREVENTION STUDY 2
The CSPS-2 trial was designed to establish noninferiority of cilostazol when compared to
aspirin.11 Similar to the CSPS trial, the CSPS-2 trial was conducted exclusively in Japan at 278
sites between December 2003 and December 2008. Patients (N = 2672; 72% male) between the
ages of 20 and 79 years with a prior cerebral infarction within the past 6.5 months, with no
evidence of cardiogenic emboli, were randomized in double-blinded fashion to receive cilostazol
100 mg orally twice daily (n = 1337) or aspirin 81 mg orally once daily (n = 1335) for 1-5 years.
Patients were excluded if they had contraindications to cilostazol or aspirin, congestive heart
failure, peptic ulcer disease, renal failure, liver disease, cardiac diseases associated with
cardioemboli, or planned revascularization procedures. Prior to study entry, 83% of patients were
receiving either cilostazol (25%) or aspirin (58%), although concurrent use of thienopyridines or
other drugs affecting platelet function or hemostasis was prohibited. The primary endpoint was
the first recurrence of stroke (cerebral infarction, cerebral hemorrhage, or subarachnoid
hemorrhage). Secondary endpoints included death from any cause, ICH, cardiovascular events,
and hemorrhage requiring hospital admission.
Baseline characteristics of the 2 groups were comparable overall, with the exception of
significantly higher percentages of patients in the aspirin arm receiving lipid-lowering (30% vs
27%; p = 0.03) and antihypertensive medications (75% vs 67%; p < 0.0001). Blood pressures,
however, were similarly controlled in both groups throughout the study period. A large
proportion of patients (92%) had modified Rankin scores of 0-2, while 46% of patients had a
score of 1. Similar proportions of patients had prior subtypes of lacunar infarcts (65% in both
groups) and atherothrombotic strokes (cilostazol 33% vs aspirin 31%).11
Data from the Antithrombotic Trialists’ Collaboration meta-analysis of antiplatelet therapy in
patients with cerebral infarction and the CSPS trial results suggested hazard ratios of 0.6 for
aspirin and cilostazol when compared to placebo.28 As a result, a predefined hazard ratio of 1.33
for the noninferiority of cilostazol was set prior to initiation of the CSPS-2 trial.11 The adjusted
significance level for superiority testing was set at 0.0471.
After a mean duration of treatment of 2.4 years, treatment with cilostazol was associated with
significant reductions in the primary endpoint of stroke, as there were 82 strokes in the cilostazol
group and 119 strokes in the aspirin group (event rates 2.76%/year vs 3.71%/year, respectively;
RRR 25.7%; p = 0.0357). The p value was lower than the adjusted level of significance for
testing of superiority (p = 0.0471); therefore, a conclusion that cilostazol may be superior to
aspirin 81 mg daily for the secondary prevention of any stroke is plausible. The secondary
endpoint of cerebral infarction, however, demonstrated similar efficacy between cilostazol and

aspirin, as event rates were 2.43% and 2.75% per person-year, respectively (p = 0.419).
Consequently, the comparative efficacies of cilostazol and aspirin for the secondary prevention
of ischemic stroke are similar. No differences were observed in the incidences of death or
cardiovascular events.11
As observed in the CASISP study, the risk of hemorrhagic events was notably lower in the
cilostazol group, as hemorrhagic events occurred in 57 aspirin-treated patients and only 23
cilostazol-treated patients (RRR 54.2%; p = 0.0004). The composite of symptomatic cerebral,
thalamic, intraventricular, cerebellar, or putamen hemorrhages occurred less frequently with
cilostazol than aspirin (8 vs 27; p = 0.0027), as did the rate of hospitalization secondary to GI
bleeding (21 vs 8; p = 0.026). As seen in the CSPS trial, patients receiving cilostazol in the
CSPS-2 trial reported significantly higher rates of mild headaches (23% vs 16%; p < 0.0001),
palpitations (12% vs 5%; p < 0.0001), and tachycardia (7% vs 2%; p < 0.0001). Overall, a higher
percentage of patients in the cilostazol group discontinued treatment (20% vs 12%) due to
adverse effects.11
While cilostazol resulted in a 41.7% RRR compared to placebo in CSPS and a 38.1% RRR
compared to aspirin in the CASISP study, decisive conclusions regarding the comparative
efficacy between cilostazol and aspirin could not be made. In the CSPS-2 trial, the treatment
effects of aspirin and cilostazol in the 83% of patients taking these medications prior to study
initiation cannot be ascertained. Early initiation of antiplatelet therapy for secondary prevention
is essential, but the CSPS-2 study is confounded by the late start date of the study drugs, as only
31% of patients in each treatment arm were initiated on their study drugs within 28 days from the
onset of cerebral infarction.11 Stroke recurrence rates are estimated to be highest (8.6% of
patients) within the first 6 months of the first incident.29 More recent data suggest recurrence
rates up to 18% at 3 months after a TIA or stroke.30 It is therefore difficult to accurately quantify
the impact of cilostazol on secondary stroke prevention given these study limitations.
The results of CSPS-2, however, support the findings of the CASISP study and demonstrate that
cilostazol significantly lowers the risks of stroke and cerebral hemorrhage when compared to low
doses (81-100 mg daily) of aspirin.11 The reduction in the composite stroke endpoint is likely
driven by significant reductions in hemorrhagic stroke and the comparative efficacies of aspirin
and cilostazol specific to ischemic stroke are similar.
CILOSTAZOL BLEEDING EVENTS
Trials that evaluate bleeding risk with antithrombotic therapies vary in their definition and
classification of hemorrhagic events. These descriptions depend on the assessment method used
when either a universal definition was not available or not utilized at the time of data collection.
In addition, the description of a bleeding event and its severity are sometimes inadequately
defined, leaving the bleeding risk and severity of a given antithrombotic agent somewhat open to
reader interpretation. Consequently, it proves difficult to accurately stratify and compare
severities of bleeding events between studies that evaluate safety. A literature-based effort to
classify the terminology for hemorrhagic events is provided below.

Any bleeding includes major and minor hemorrhagic events, but intracranial bleeding cases may
be omitted depending on the trial.14,31,32 The definition of major bleeding can vary, but it
typically includes bleeding with persistent sequelae that contributes to significant disability,
intraocular bleeding leading to significant vision loss, transfusion of 3 or more units of packed
red blood cells, or need for hospitalization. A major hemorrhagic event may be life-threatening
or non–life-threatening.11,31,33,34 Minor bleeding does not meet major bleeding criteria and may
include epistaxis or other bleeding that does not require transfusion, cause disability, or require
hospitalization.31,34 Life-threatening bleeding generally refers to a fatal bleeding event, a
decrease in hemoglobin of 5 g/dL or more, significant hypotension requiring inotropic support,
symptomatic intracranial hemorrhage, need for emergent surgical intervention, or need for
transfusion of 4 units or more of packed red blood cells.33,34
Despite these inherent limitations that complicate comparisons, the bleeding incidences reported
in various stroke trials that included placebo, cilostazol, aspirin, dipyridamole, and/or clopidogrel
are reported with p values and confidence intervals, when available, in Table 2.31–37
Table 2. Major, Minor, and Fatal or Life-Threatening Bleeding in Secondary Stroke Prevention Trials

Drug
Cilostazol

Major Bleeding
Incidence (%)
0.28a

Minor Bleeding
Incidence (%)
Not defined

Fatal or LifeThreatening Bleeding
Incidence (%)
None reported

Studies
Shinohara (2010),11
Gotoh (2000),14 Huang
(2008)15
Dipyridamole
Diener (1996)31
0.4
Not defined
0.4
Clopidogrel
Diener (2004),33 Sacco 1-3.6
1
1
(2008),34 CAPRIE
steering committee
(1996)32
Aspirin (30-325
CAPRIE steering
1.95-3.9
12.2
0.8-1.2
mg/day)
committee (1996),32
ESPRIT study group
(2006),35 CAST
collaborative group
(1997),36 IST
collaborative group
(1997)37
Aspirin + clopidogrel
Diener (2004)33
2
3
3
Aspirin + dipyridamole Diener (1996),31Sacco
2.6-4.1
12.5
1.6
(2008),34 ESPRIT
study group (2006)35
a
A cilostazol meta-analysis demonstrated that the serious bleeding incidence in peripheral arterial disease populations ranges
from 0.4% to 2.8%.38

Data from these trials demonstrate lower rates of major bleeding, including intracerebral
hemorrhages, associated with cilostazol use when compared to other AHA-approved antiplatelet
agents for secondary stroke prevention. A meta-analysis of cilostazol trials demonstrated that the
serious bleeding incidence in peripheral arterial disease populations ranges from 0.4% to 2.8%.38
Discussion
Collective data from the CSPS, CASISP, and CSPS-2 trials suggest that cilostazol may be more
effective than aspirin in the secondary prevention of stroke and is associated with lower rates of

hemorrhagic stroke in the Asian population.11,14,15 While the primary endpoint in CASISP did not
reach statistical significance, this may be a direct result of small sample size and short follow-up
period. On the basis of this collective evidence, Japanese guidelines for the management of
stroke recommend cilostazol as a treatment alternative for secondary prevention of cerebral
infarction.39
The use of aspirin as a first-line agent for the secondary prevention of ischemic stroke is
supported by the AHA and American Stroke Association.2 The low NNT of 42 patients for
secondary stroke prevention with cilostazol in the CSPS trial is comparable to the NNT of 35
patients when low-dose aspirin (50 mg daily) was compared to placebo for secondary stroke
prevention in the European Stroke Prevention Study 2 (ESPS-2), a study in which aspirin alone
resulted in a 21% RRR compared to placebo.31 While cilostazol resulted in a 42% RRR
compared to placebo in CSPS,14 direct comparisons between the efficacy of cilostazol and
aspirin in the CSPS and ESPS-2 trials are not statistically valid due to differences in patient
demographics, as CSPS was conducted exclusively in Asian patients while ESPS-2 participants
were primarily white. Additionally, the large differences in the percentages of patients with
ischemic heart disease and diabetes in these 2 trials make it difficult to directly compare the
efficacy of cilostazol and aspirin across trials.
Calculations from the Antiplatelet and Antithrombotic Trialists’ Collaboration data demonstrate
that aspirin and thienopyridines are associated with an NNT of 26-28 patients to prevent one
stroke in a 2.5- to 3-year treatment period.28,40 The NNT for cilostazol from a subgroup analysis
of hypertensive or diabetic patients in the CSPS study was 18.7 patients per 3-year treatment
period.41
Despite these promising data, uncertainty regarding cilostazol's utility as a first-line agent for
secondary stroke prevention remains. The AHA/American Stroke Association have identified
racial disparities in stroke care of Asian American patients and recommend more research in this
population.42 Further prospective, randomized trials are warranted in a more diverse patient
population to determine if the benefits of cilostazol on stroke reduction are universal or specific
to the Chinese and Japanese patient populations. Treatment with cilostazol is significantly more
expensive than treatment with over-the-counter aspirin. Additionally, while the risk of major
bleeding is lower with cilostazol in the Asian study population, a high rate of discontinuation
(20%) due to adverse effects was associated with cilostazol use in the CSPS-2 trial. Although
cilostazol has been proven to reduce incidence of hemorrhagic strokes, it has not yet been proven
to be more effective than aspirin in the secondary prevention of strokes that are ischemic in
nature.
While cilostazol's antiplatelet effects occur within 3-6 hours of initiation,8 prospective clinical
data supporting its use in the treatment of acute (<48 hours) ischemic stroke are limited to one
small study that demonstrated noninferiority and similar rates of bleeding with cilostazol 200 mg
daily when compared to aspirin 300 mg.43 Treatment with cilostazol should therefore be reserved
as an option for secondary prevention in Asian patients who have already received treatment
with an appropriate alternative antiplatelet agent. Based on available data, the optimal time to
initiate treatment with cilostazol after ischemic stroke remains undefined and warrants further
investigation.

Summary
Cilostazol use for the secondary prevention of stroke may be optimal for Asian patients at high
risk of hemorrhagic events or intolerant to aspirin. However, further large-scale trials with more
heterogeneous study populations are warranted before treatment with cilostazol can be
universally recommended as a first-line pharmacologic agent for secondary stroke prevention.
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